Loading...
Loading...
BMY| Name | Value |
|---|---|
| Revenues | 11.0B |
| Cost of Revenue | 2.5B |
| Gross Profit | 8.5B |
| Operating Expense | 4.2B |
| Operating I/L | 4.2B |
| Other Income/Expense | -2.1B |
| Interest Income | 0.1B |
| Pretax | 2.1B |
| Income Tax Expense | 0.2B |
| Net Income/Loss | 1.9B |
Bristol-Myers Squibb Company is a global biopharmaceutical company specializing in the discovery, development, and commercialization of innovative medicines. Its product portfolio includes treatments for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. Key products such as Revlimid, Eliquis, Opdivo, and Orencia cater to various therapeutic areas, generating revenue through sales to wholesalers, distributors, pharmacies, hospitals, clinics, and government agencies. The company's focus on biopharmaceutical products and its diverse range of offerings positions it as a significant player in the healthcare industry, driving its revenue and growth.
